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A B S T R A C T   
Complications related to atherosclerosis account for approximately 1 in 4 deaths in the United States and 
treatment has focused on lowering serum LDL-cholesterol levels with statins. However, approximately 50% of 
those diagnosed with atherosclerosis have blood cholesterol levels within normal parameters. Human fortilin is 
an anti-apoptotic protein and a factor in macrophage-mediated atherosclerosis and is hypothesized to protect 
inflammatory macrophages from apoptosis, leading to subsequent cardiac pathogenesis. Fortilin is unique 
because it provides a novel drug target for atherosclerosis that goes beyond lowering cholesterol and utilization 
of a solution nuclear magnetic resonance (NMR) spectroscopy, structure-based drug discovery approach requires 
milligram quantities of pure, bioactive, recombinant fortilin. Here, we designed expression constructs with 
different affinity tags and protease cleavage sites to find optimal conditions to obtain the quantity and purity of 
protein necessary for structure activity relationship studies. Plasmids encoding fortilin with maltose binding 
protein (MBP), 6-histidine (6His) and glutathione-S-transferase (GST), N- terminal affinity tags were expressed 
and purified from Escherichia coli (E. coli). Cleavage sites with tobacco etch virus (TEV) protease and human 
rhinovirus (HRV) 3C protease were assessed. Despite high levels of expression of soluble protein, the fusion 
constructs were resistant to proteinases without the inclusion of amino acids between the cleavage site and N- 
terminus. We surveyed constructs with increasing lengths of glycine/serine (GGS) linkers between the cleavage 
site and fortilin and found that inclusion of at least one GGS insert led to successful protease cleavage and pure 
fortilin with conserved binding to calcium as measured by NMR.   
1. Introduction 
Atherosclerosis, or the hardening and narrowing of arterial walls, is 
the leading cause of death worldwide [1]. Atherosclerogenesis occurs 
when low density lipoproteins (LDL) in plasma diffuse into the intima of 
arteries and then become oxidized (oxLDL), followed by uptake into 
macrophages. Macrophages eventually form foam cells, which over time 
develop into plaques on the arteries, leading to blockages in blood flow 
that cause cardiac events such as infarction, stroke, hypertension, etc. 
Presently, medications used to treat atherosclerosis largely depend on 
inhibiting the formation of cholesterol in vivo via the use of statins, 
which can cause undesirable side effects. For example, HMG-CoA 
reductase inhibitors (statin drug class) can cause leg cramps in 
patients at night that lead to decreased compliance with treatment [2]. 
Additional side effects may include cataracts and short-term memory 
loss [3]. Moreover, a recent study of 136,905 people showed that nearly 
half of all patients brought into the emergency room with heart attacks 
had normal to low LDL levels in their blood [4]. This finding made 
evident the need to develop drugs that target other mechanisms in the 
pathology of atherosclerosis than the in vivo formation of high 
cholesterol. 
Fortilin is a promising drug target to treat atherosclerosis [5]. Also 
known as translationally controlled tumor protein (TCTP) or histamine 
releasing factor (HRF), fortilin is a highly conserved anti-apoptotic 
protein [6]. Fortilin consists of 172 amino acids and is found 
throughout the human body; in the cytosol, nucleus, and mitochondria 
of all cell types, blood and extracellular space [7,8]. Fortilin exerts its 
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anti-apoptotic effect through multiple mechanisms including calcium 
complexation and p53 inactivation, but it contributes to atherosclerosis 
by keeping macrophages in the M1 pro-inflammatory phenotype [5,9]. 
Fortilin has been implicated in the progression of atherosclerosis by 
reducing macrophage apoptosis by binding to and inhibiting p53, a 
transcription factor that regulates the transcription of BAX, a 
pro-apoptotic protein. This mechanism promotes foam cell formation, 
leading to deposits on arterial walls [9]. Fortilin also exhibits 
anti-apoptotic activity by scavenging free calcium in the cytoplasm of 
cells, thus exerting a protective effect from calcium-induced apoptosis 
[10]. Specifically, inhibition of the pro-survival activity of could provide 
an orthogonal strategy to treat atherosclerosis by shutting down the 
protective effects of fortilin. 
Fortilin is a 19 kDa protein that has 11 beta-strands and an extended 
flexible loop between residues Arg36 and Ile67 (Fig. 1A). The amino- 
and carboxy-termini are in proximity to one another, creating a cavity 
that could be interrogated for small molecule binding. The calcium 
binding site is coordinated by six oxygen atoms within the beta barrel 
among residues N131, Q133, L149 and D150 (Fig. 1B) [11]. While a 
direct connection between fortilin, calcium scavenging, and athero-
sclerosis has not yet been made, calcium-dependent apoptosis does 
occur during ox-LDL-induced apoptosis and it is hypothesized that for-
tilin could play a role through its calcium scavenging activity [12]. 
A structure-based approach to targeting fortilin will provide impor-
tant information for drug screening and defining drug binding sites. 
Structure-based drug design (SBDD) is a technique commonly used to 
create small molecule therapeutics that specifically target a given pro-
tein [13,14]. Solution nuclear magnetic resonance spectroscopy (NMR) 
is an excellent tool for SBDD, for example, in screening small molecule 
inhibitors (SMIs), mapping binding hot spots, and determining binding 
affinities and kinetics [14]. A solution structure of recombinant fortilin 
has been reported using NMR [11]. Feng et al., used a construct with a 
6His affinity tag and required high salt (200 mM) conditions for high 
quality NMR spectra. 
NMR experiments require milligram quantities of pure, isotopically 
enriched, and bioactive protein. E. coli expression platforms are 
routinely used as they allow for straightforward, high yield and 
affordable isotope enrichment. Affinity tags are often used for protein 
purification [15]. Ideally, the affinity tags should be removed by enzy-
matic cleavage to ensure no pseudo binding effects due to the presence 
of the affinity tag. The N- and C-termini of fortilin form a beta strand that 
forms a pocket in the native fortilin structure. Affinity tags attached at 
either the N- or C-terminus complicate the potential to target this site. 
Functional studies of fortilin with an affinity tag are inconclusive due to 
the presence of the affinity tag at the suspected site of small molecule 
binding site [16,17]. Here, we describe the design and assessment of 
several fortilin constructs for the purpose of expressing and purifying a 
recombinant fortilin molecule with minimal non-native residues. In-
clusion of a short GGS linker between an HRV 3C protease cleavage site 
and the N-terminus of fortilin resulted in milligram quantity of isoto-
pically enriched 15N GGS-fortilin. Calcium binding was observed by 
NMR titrations, demonstrating the structure and activity of this 
construct were maintained. The work presented here shows that pure 
recombinant fortilin can be proteolytically cleaved from an affinity tag 
and retain biological activity by the insertion of a GGS linker sequence. 
2. Results and discussion 
Initial efforts to produce recombinant tag-less fortilin were hindered 
by low or no cleavage with either TEV or HRV 3C proteases directed at 
Abbreviations 
IPTG isopropyl-β-d-1-thiopyranogalactoside 
TEV tobacco etch virus 
HRV 3C human rhinovirus 3C protease 
MBP maltose binding protein 
GST glutathione-S-transferase 
6His 6-histidine 
OSM oncostatin M 
NMR nuclear magnetic resonance 
SMI small molecule inhibitor 
TCTP translationally controlled tumor protein 
HRF histamine release factor 
LDL low density lipoprotein 
oxLDL oxidized LDL 
PRX-1 peroxiredoxin-1 
PTM posttranslational modification 
LB Luria Bertani 
PBS phosphate buffered saline 
CV column volume  
Fig. 1. Calcium-bound fortilin. A) Side view of fortilin (blue) bound to calcium (magenta) with residues labeled for the flexible loop, the N- and C-termini, and B) 
downward view of fortilin bound to calcium with complexed oxygen atoms (red) shown and residues in proximity displayed as sticks. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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N-terminal cleavage sites with either 6His, maltose binding protein 
(MBP), glutathione-S-transferase, or 6His-MBP affinity tag constructs 
(Fig. 2). Observed cleavage efficiencies for these constructs led to 
development of a systematic approach to define a minimal linker length 
required for effective and efficient affinity tag removal. 
2.1. Expression and purification of recombinant human fortilin 
Each fortilin construct was made using the ATUM pD441 T5 IPTG 
inducible promoter system. For each of the constructs used, soluble and 
high purity quantities from 100 mL LB cultures grown at 37 ◦C were 
successful. After affinity chromatography using glutathione agarose to 
purify the (GGS)N constructs, GST-(GGS)N-fortilin was purified typically 
with some GST protein made during the protein expression process (SI. 
Figs. 1–3, 5). For cleavage analysis, the cleaved fortilin construct was 
compared to the un-cleaved construct, so we decided not to purify 
further than affinity chromatography for this reason. The same occurred 
with the MBP-containing constructs where some MBP protein was eluted 
during affinity chromatography with the desired purified protein (SI. 
Figs. 4 and 6). Samples containing pure MBP construct were combined 
and concentrated to workable small volumes for cleavage with either 
TEV or 3C protease. For the initial cleavage analysis, all constructs were 
grown at smaller culture volumes (100 mL) to save on materials. The 
construct we decided to use for NMR titration analysis was the GST-GGS- 
fortilin construct because cleavage with 3C protease provided the fewest 
amino acids remaining at the N-terminus of the protein, leaving only 
GGS-fortilin (SI. Fig. 7). The yield from a 1 L, 15N-labeled culture was 
2.08 mg by a reading of the A280 and an ε value of 0.595 (mL/mg)− 1 
cm− 1. This was an ideal amount for an approximately 200 μM sample for 
NMR titration analysis. 
2.2. Protease cleavage sites distal to fortilin increases MBP removal 
effectiveness 
After treatment of up to 48 h with TEV protease, there was no evi-
dence by SDS-PAGE that the 6His-TEV-fortilin exhibited any cleavage 
(Fig. 4, lanes 7–10). Next, MBP-TEV-fortilin was treated TEV protease 
for up to 48 h at room temperature, with again no evidence of cleavage 
(Fig. 3, lanes 9–12). A construct consisting of 6His-MBP-10N–3C-TEV- 
fortilin treated with TEV again showed no evidence of cleavage (Fig. 3, 
lanes 4 and 7). TEV activity was validated with a positive control of 
MBP-TEV-OSM, or Oncostatin M, a construct known to cleave success-
fully upon addition of TEV protease [18]. Interestingly, the 
6His-MBP-10N–3C-TEV-fortilin construct contained an 3C HRV protease 
cleavage site distal to the N-terminal site that was left intact after 
cloning in the TEV site. Treatment with 3C resulted in 72% cleavage 
after 24 h with no further cleavage after 48 h (Fig. 3, lanes 5 & 8). 
2.3. Protease cleavage sites distal to fortilin increases GST removal 
effectiveness 
The GST-3C-TEV-fortilin construct showed no cleavage after two 
days of incubation with TEV protease (day 2 data not shown). However, 
upon incubation with HRV 3C protease, cleavage was observed after 24 
h. TEV-fortilin is indicated by an arrow in Fig. 4. No cleavage was 
observed for the 6His-TEV-fortilin construct upon addition of TEV pro-
tease after 48 h of incubation at room temperature. The 6His-TEV-forti-
lin band was confirmed by mass spectrometry, demonstrating no 
cleavage. 
Fig. 2. Constructs used for recombinant fortilin expression, purification, and cleavage. All constructs were made in ATUM’s pD441-SR vector.  
Fig. 3. MBP construct cleavage reactions. SDS-PAGE gel of TEV and 3C pro-
tease cleavage reactions. Cleavage reactions of MBP constructs against a posi-
tive control lane of MBP-TEV-OSM. Uncleaved MBP-TEV-fortilin can be seen to 
appear at approximately 62 kDa on a 4–12% SDS-PAGE gradient gel. A band at 
42 kDa indicates the MBP affinity tag, presumably due to abortive translations 
for the MBP-TEV-fortilin construct. Arrows indicate successfully cleaved 
TEV-fortilin. 
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2.4. A minimum GGS tripeptide is required for efficient protease cleavage 
It is well-documented that affinity tags can introduce steric hin-
drance, making the enzymatic cleavage less efficient. Further, the 6His- 
MBP-10N–3C-TEV-fortilin construct has an additional Human 3C 
rhinovirus protease cleavage site N-terminal to the TEV cleavage site. 
Treatment of the 6His-MBP-10N–3C-TEV-fortilin with 3C protease after 
24 h at 4 ◦C resulted in 72% cleaved fortilin. However, this construct was 
undesirable because it left additional 3C (Leu-Glu-Val-Leu-Phe-Gln-Gly- 
Pro) and TEV (Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Ser) amino acids; further, 
there was no additional cleavage observed after 48 h. These observa-
tions led us to hypothesize that for efficient cleavage, a linker was 
needed between the protease cleave site and the fortilin protein. 
We systematically investigated what minimum linker length was 
required for efficient protease cleavage. We used (GGS)N linker se-
quences where N = 0, 1, 2 or 3. We found that the inclusion of just one 
GGS linker sequence (GGS)1 led to cleaved fortilin with the sequence 
GGS-fortilin; this result was verified against a negative control of 
(GGS)0, as well as no addition of HRV 3C protease. While additional 
linker sequences proved successful, we moved forward with (GGS)1- 
fortilin for NMR analysis to minimize N-terminal binding interference by 
tag amino acids. 
Incorporating a Gly-Gly-Ser (GGS) linker between the protease 
cleavage site and fortilin increased enzymatic protease cleavage effi-
ciency. We chose to incorporate a repeating GGS motif between the 
protease cleavage site and fortilin. GGS motifs were chosen for their 
flexibility, experimentally determined random coil behavior, and charge 
neutrality [19,20]. GGS linker units were either not included in the 
construct (GGS)0 or included in increasing repeats of GGS from (GGS)1 
to (GGS)3. Addition of just one GGS linker to the N-terminus of fortilin 
was sufficient to produce a successfully cleaved construct, with 
approximately 86.5% cleavage GGS-fortilin after treatment with 3C 
protease (Table 1). Addition of two GGS linker sequences provided 
81.5% cleavage, and addition of three GGS linkers resulted in 85% 
cleavage efficiency. Confirmation of cleavage reactions was analyzed by 
SDS-PAGE (Fig. 5) and compared to a positive control of GST-3C-Syk 
protein to ensure protease activity. All samples were also compared 
against negative controls wherein no protease was added. Addition of 
extra (GGS)N linkers showed no increase in cleavage efficiency. Addition 
of one GGS linker sequence at the N-terminus of fortilin appeared to 
have provided sufficient access for a protease to cleave the affinity tag 
from fortilin for biological studies. Recovery yields after protease 
cleavage are available in Table 1. Yields were quantified in comparison 
to the respective non-cleaved construct on the same SDS gel. 
2.5. Calcium titration of (GGS)1-fortilin 
It is well established that fortilin binds to calcium and the binding 
site has been characterized (see Fig. 1) [11,22,23]. For the present study, 
we reproduced CaCl2 titration analysis with the 15N-labeled 
(GGS)1-fortilin protein using NMR spectroscopy and obtained a Kd value 
of 13 μM, which is within reason to previously reported affinities of 
fortilin for Ca2+ [11]. Multiple literature reports provide the Kd values 
for calcium binding to fortilin that range from 10 μM to 17.5 μM to 22 
mM and 25 mM [10,11,24]. The present study shows that recombinant 
fortilin, in the absence of an affinity tag, still binds calcium. Biologically, 
fortilin binds calcium to mediate histamine release from basophils, 
which play a critical role in immune system function [6]. 
Fig. 4. Protease cleavage sites located proximal to the N-terminus are resistant 
to cleavage. Cleavage reactions of GST and 6His constructs against a positive 
control lane of MBP-TEV-OSM. Protein ladder is shown in the first lane to 
indicate molecular weight markers on a 4–12% bis-acrylamide gradient SDS 
gel. The arrow indicates successfully cleaved TEV-fortilin, where the 3C 
cleavage site is N-terminal to the TEV protease cleavage site. 
Table 1 
Percent yield of tag free fortilin after one day to cleave constructs. Yields 
quantified using SDS PAGE image analysis using GelAnalyzer [21].  
Construct Cleaved 
construct 
Percent (%) recovery of cleaved 
fortilin 




GST-3C-TEV-fortilin TEV-fortilin 28 
GST-3C-(GGS)0-fortilin fortilin 0.5 
GST-3C-(GGS)1-fortilin GGS-fortilin 86.5 
GST-3C-(GGS)2-fortilin (GGS)2-fortilin 81.5 
GST-3C-(GGS)3-fortilin (GGS)3-fortilin 85  
Fig. 5. Cleavage reactions of (GGS)N constructs where N = 0, 1, 2 or 3 against a 
positive control lane of cleaved GST-3C-Syk. Protein ladder is shown in the first 
lane to indicate molecular weight markers on a 4–12% polyacrylamide SDS 
gradient gel. Arrow indicates successfully cleaved (GGS)N-fortilin that was 
confirmed by mass spectrometry. 
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A 1 M aqueous solution of calcium chloride (CaCl2) was titrated into 
a solution of 176 μM (GGS)1-fortilin. Aliquots of 1 μL CaCl2 were used for 
each titration point for a total of 6 points. Notable peak shifts in the 
titration can be seen in Fig. 6 where arrows indicate increasing con-
centrations of CaCl2. The combined chemical shifts were calculated for 
Y132 and a quadratic expansion of the isotherm binding model binding 
isotherm was fit to the data to yield a binding affinity of Kd of 14 mM ±
3.6 mM. 
3. Conclusion 
The successful cleavage of the 6His-MBP-10N–3C-TEV-fortilin and 
GST-3C-TEV-fortilin constructs led us to the hypothesis that, at the N- 
terminus, space is required for a protease searching for a cleavage 
recognition sequence to gain access to the cleavage site. Insertion of just 
one GGS linker sequence, at the N-terminus and before the cleavage site, 
provided 78% recovery of GGS-fortilin (Fig. 5). Further characterization 
of this activity needs to be done to determine the mechanism by which 
native fortilin hinders protease activity at the N-terminus. According to 
computational ligand docking studies performed by our lab that were 
consistent with a previous study, the N-terminus is a predicted location 
for small molecule binders and is required for activity [25,26]. Addi-
tionally, the N-terminus has been shown to be highly conserved among 
various species and is required for anti-apoptotic activity of fortilin both 
in vivo and in vitro when binding to Bcl-xL, a protein that is required in 
cell survival maintenance [26]. This is experimentally backed by pre-
vious work published using Plasmodium falciparum, where the 
artemisinin binding site was characterized, and the binding site was near 
the N-terminus [17]. Indeed, previous computational work published by 
our lab has shown that fortilin binds peroxiredoxin-1 (PRX-1), a protein 
implicated in reactive oxygen species (ROS)-mediated apoptosis, near 
the N-terminus [27]. It should be noted, however, that to date the 
binding site for artemisinin or dihydroartemisinin (DHA) has not been 
characterized in human fortilin, while evidence suggests that DHA does 
bind human fortilin [16,17]. 
The present study has shown that recombinant, pure, isotopically 
labeled fortilin can be produced with a cleavable affinity tag when just 
one GGS linker is added to the N-terminus. This indicates that the N- 
terminus is partially hidden from protease in the absence of the linker 
sequence. More studies need to be performed to not only determine the 
mechanism by which addition of a GGS sequence facilitates cleavage, 
but to also characterize the interaction of small molecules at the N-ter-
minus, such as artemisinin and DHA, which bind but have not been 
characterized in human recombinant fortilin [16,17]. Additionally, 
NMR studies need to be performed on fortilin in other expression sys-
tems, such as yeast, to explore the possibility of post-translational 
modifications (PTMs), and to determine the differences in binding be-
tween recombinant fortilin products in E. coli, P. pastoris, and human cell 
lines. 
4. Materials and methods 
4.1. Reagents 
Unless otherwise mentioned, chemical reagents were purchased 
from Fisher Scientific (Waltham, MA). Isotopically enriched reagents 
were purchased from MilliPoreSigma (St Louis, MO). 
4.1.1. Expression and purification of S219V TEV protease from E. coli 
Recombinant TEV protease was expressed and purified using 
pRK793 [28] (a gift from David Waugh (Addgene plasmid # 8827; 
http://n2t.net/addgene:8827; RRID:Addgene_8827)) in BL21 (DE3) 
strain E. coli. From a glycerol stock, 20 mL of Luria Bertani (LB) broth 
containing 100 μg/mL ampicillin, 25 μg/mL chloramphenicol was 
inoculated, and incubated overnight at 37 ◦C with shaking at 200 rpm. 
This overnight culture was then used to inoculate 1L LB containing 100 
μg/mL ampicillin, 25 μg/mL chloramphenicol with shaking at 37 ◦C 
with 200 rpm. Once the OD600 reached between 0.5 and 0.7, a 
pre-induction sample equivalent to 1 mL of cells at OD600 of 0.8 was 
collected, and the culture flasks placed on ice and gently rotated every 
few minutes to cool the cultures. The incubator was then set to 30 ◦C and 
the cultures were reintroduced at the elevated temperature and 
expression was induced with 1 mM IPTG, with shaking at 200 rpm. This 
culture was incubated overnight. On the third day, a post-induction 
sample equivalent to 1 mL of cells at OD600 of 0.8. The pre- and 
post-induction samples were used to analyze expression using 
SDS-PAGE. Lysis was halted by pouring the cultures into pre-weighed 
500 mL centrifuge bottles and the cultures centrifuged at 6000×g for 
30 min at 4 ◦C. After centrifugation, the supernatants were removed, and 
the mass of the pelleted bacteria weighed. The pellet was resuspended in 
40 mL of lysis buffer consisting of 50 mM Tris-Cl pH 8.0, 300 mM NaCl, 
20 mM imidazole, 10% (w/v) sorbitol, 20 mM β− mercaptoethanol, 0.02 
mg/mL lysozyme, and 1X HALT protease inhibitors (Thermofisher, 
USA). The suspension was sonicated on ice water at 60% power, 30 s 
on/30 s off for 4.5 min of total pulse time and a 75 μl sample collected 
for SDS-PAGE to check post sonication pellet and supernatant. The 
sonicated suspension was centrifuged at 16,000×g for 30 min at 4 ◦C. 
The supernatant was collected and filtered using a 0.45 μm PES filter. To 
the filtered lysate, 5 mL of Ni-NTA superflow slurry (Qiagen Cat 
#30410/30,430) was added and the mixture incubated overnight at 4 ◦C 
with rocking. On the fourth day, the lysate/resin mix was loaded into a 
column and the flow through collected. Purification was carried out with 
a BioLogic LP System using EconoColumn 1.0 × 10 cm chromatography 
Fig. 6. 1H,15N HSQC spectral overlay of GGS-fortilin titrated with calcium. 
Y132, Y151, N131, Q133, and H77 are labeled with arrows indicating 
increasing concentrations of calcium. 
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columns (Bio-Rad, Hercules, CA, USA). To line A, the lysis buffer 
described previously was attached. To line B, the same lysis buffer with 
the only difference being a 300 mM imidazole concentration was 
attached. Buffer A was run over the column at a flow rate of 1.0 mL/min 
until the A280 stabilized, all while collecting the flow through. The 
program for protein purification was as follows: Line A for 10 min, Line 
B (0%–100% B, 1.0 mL/min) for 60 min, hold Line B for 10 min, and 
back to 100% A for 10 min. Results were evaluated by SDS-PAGE. 
Fractions containing purified TEV protease were combined, and pro-
tein concentration determined by absorbance at 280 nm. Pooled frac-
tions were diluted to a final concentration of 1 mg/mL in a 50% glycerol 
solution, and 0.5 mL aliquots stored at − 80 ◦C. 
4.1.2. Expression plasmid constructs 
Plasmids were purchased from ATUM (Newark, CA) using their 
pD441-SR vector. These constructs consisted of glutathione S-trans-
ferase (GST), maltose binding protein (MBP), and 6-histidine (6His) 
affinity tags, human rhinovirus (HRV) 3C and tobacco etch virus (TEV) 
protease recognition sites, and glycine-glycine-serine (GGS) linkers of 
varying length (GGS)N where N = 0, 1, 2 or 3 at the N-terminus of fortilin 
in the pD441-SR expression vector. 
4.1.3. Expression of recombinant fusion proteins 
Plasmids were transformed into 50 μL of competent E. coli cells using 
the heat-shock method at 42 ◦C. Single colonies were inoculated into 5 
mL of LB medium containing 50 μg/mL kanamycin and grown at 37 ◦C 
overnight with shaking at 250 rpm. One mL of each overnight culture 
was inoculated into 100 mL LB medium containing 50 μg/mL kanamycin 
and grown at 37 ◦C with shaking at 250 rpm until the OD600 reached 
between 0.60 and 0.80. Once reached, IPTG was added to 0.1 mM to 
induce protein expression. Expression continued at these conditions for 
6 h. Cells were harvested by centrifugation at 4,000×g for 20 min and 
expression was assessed by SDS-PAGE on 4–12% bis-acrylamide 
gradient gels. 
4.1.4. Expression of 15N-labeled recombinant fusion proteins for NMR 
spectroscopy 
Plasmids were transformed into 50 μL of competent E. coli cells using 
the heat-shock method at 42 ◦C. Single colonies were inoculated into 5 
mL of LB medium containing 50 μg/mL kanamycin and grown at 37 ◦C 
and grown for approximately 8 h. One mL of each culture was inoculated 
into 50 mL of 15N-labeled M9 minimal media containing 50 μg/mL 
kanamycin and grown at 37 ◦C overnight. 
4.1.5. Cell lysis 
Cell pellets (approximately 0.13 g each) from 100 mL cultures were 
resuspended in 2 mL lysis buffer containing 1X phosphate buffered sa-
line (PBS), pH 7.4 and 0.1% Triton X-100. Lysozyme was added to a final 
concentration of 0.25 mg/mL as well as ½ tablet of HALT protease in-
hibitor cocktail (Pierce, Rockford, IL). The lysate was then subjected to 
sonication at 70% power for 30 s on/30 s off for a total of 2 min. Samples 
were then centrifuged at 17,000×g for 45 min at 4 ◦C. The resulting 
lysate was filtered through a 0.45 μm PES filter and subjected to affinity 
purification. 
4.1.6. Purification of GST-3C-(GGS)N-fortilin and GST-3C-TEV-fortilin 
from BL21(DE3) cells 
GSTrap sepharose 4B 1 mL pre-packed columns were used for puri-
fication (GE Healthcare, Marlborough, MA). Separate columns were 
used for each linker sequence to avoid contamination of samples. 
Samples were loaded onto the column with a flow rate of 1.0 mL/min 
and washed with 1X PBS with a flow rate of 1.0 mL/min for 20 mL, 
followed by a 10 mL elution with GSTrap elution buffer containing 50 
mM Tris-HCl pH 8.0 and 10 mM reduced glutathione. Elution was fol-
lowed by a 10 mL wash at 1.0 mL/min with 1X PBS (Supp. Figs 1-3 and 
5). All solutions used for affinity chromatography were filtered through 
0.22 μm nylon filters and degassed under vacuum with rigorous stirring 
for at least 1 h. 
4.1.7. Purification of 6His-MBP-10N–3C-TEV-fortilin and MBP-TEV- 
fortilin 
Amylose resin (New England Biolabs, Ipswich, MA) was used for 
purification of MBP-tagged proteins. An approximately 50% slurry of 
affinity beads to 20% ethanol were used to pack a column by gravity 
until the column volume reached 3 mL. The column was equilibrated 
with 25 mL of column buffer containing 20 mM Tris-HCl pH 7.4, 0.2 M 
NaCl and 1 mM EDTA. The clarified lysate was added to the column and 
the flow through collected. This step was repeated once to improve 
protein binding. Next, the column was washed with 10 column volumes 
(CV) of the column buffer described above. This was followed by elution 
by flowing 5 CV of column buffer containing 10 mM maltose, collected 
over three elution steps. A final wash step of 10 CV column buffer was 
performed to remove any remaining protein (Supp. Figs. 4 and 6). 
4.1.8. Purification of 6His-TEV-fortilin 
Nickel agarose resin (HisPur™ Ni-NTA Superflow agarose, (Ther-
moFisher Scientific, Waltham, MA) was used for purification of 6His- 
TEV-fortilin. An approximately 50% slurry of affinity beads in 20% 
ethanol were used to pack a column by gravity until the column volume 
reached 3 mL. The column was equilibrated with 25 mL of buffer con-
taining 50 mM Tris-Cl pH 8.0, 300 mM NaCl, 20 mM imidazole. Next, 
the clarified lysate was added to the column and the flow through 
collected. This step was repeated once to improve binding to the column. 
The column was then washed with 10 CV of buffer containing 50 mM 
Tris-Cl pH 8.0, 300 mM NaCl, 20 mM imidazole. This was followed by 
elution with 5 CV of buffer containing 50 mM Tris-Cl pH 8.0, 300 mM 
NaCl, 200 mM imidazole (Supp. Fig. 5). 
4.1.9. HRV 3C cleavage of affinity tags from fusion proteins and removal of 
proteases 
Samples containing purified fusion protein containing the 3C pro-
tease site (LEVLFQ/GP) underwent cleavage with either human rhino-
virus 3C (HRV 3C) using the Pierce HRV 3C protease solution kit (Pierce, 
Rockford, IL) according to manufacture protocols. Protease removal was 
also done according to manufacture protocols by dialysis using 0.5–3.0 
mL capacity dialysis cassettes (ThermoFisher Scientific, Waltham, MA) 
into 3C cleavage buffer containing 50 mM Tris-Cl pH 7.0, 150 mM NaCl 
and 1 mM EDTA. Samples were dialyzed and cleaved with 23 μL of the 
3C protease at 4 ◦C; 25 μL of sample was checked for cleavage by SDS- 
PAGE after 24 and 48 h. For the (GGS)1 construct, the cleaved protein 
(GGS-fortilin) was buffer exchanged from protease buffer by size 
exclusion chromatography using an S75 column equilibrated within 
100 mM NH4HCO3 (Cytiva, Marlborough, MA). Fractions containing 
pure protein were combined and concentrated using 5 MWCO PES 
Vivaspin 20 columns (Sartorius, Stonehouse, UK) by centrifugation at 
4000×g until the volume reached approximately 10 mL. These were 
then aliquoted such that microcentrifuge tubes contained 2 mg protein 
each and lyophilized at 2 atm and − 80 ◦C overnight using a LabConco 
FreeZone 2.5 Plus lyophilizer (LabConco, Kansas City, MO). Samples 
were stored at − 20 ◦C. 
4.1.10. TEV protease cleavage of affinity tags from fusion proteins 
Samples containing purified fusion protein containing the tobacco 
enterovirus (TEV) protease site (ENLYFQ/SG) using in-house grown TEV 
protease (expression and purification protocol above) using 2 μL pro-
tease solution for every 200 μg of protein in the elution buffer according 
to the corresponding construct. Samples were rotated at room temper-
ature and 25 μL aliquots checked at 24 and 48 h by SDS-PAGE. 
4.1.11. SDS-PAGE analysis of protein expression, purification and cleavage 
Protein expression, purification and cleavage steps were analyzed 
using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- 
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PAGE). Samples were prepared such that equal loading was observed in 
each gel. Gels were prepared according to standard protocol and used for 
protein separation with (4–12%) resolving and stacking (6%) gels 
(Invitrogen, Carlsbad, CA). Quantification was done using GelAnalyzer 
19.1 [21]. 
4.1.12. NMR spectroscopy for activity assay via calcium titration of 
(GGS)N-fortilin 
Lyophilized (GGS)N-fortilin (1.76 mg) was resuspended in 500 μL of 
a 20 mM tris-Cl buffer, pH 8.0, containing 200 mM NaCl and 10% D2O. 
An aqueous 1 M CaCl2 stock solution was used for each titration. Spectra 
were recorded at 298 K on a Bruker AVANCE III 600 MHz spectrometer 
equipped with a 5 mm TCI cryoprobe with z-axis gradients. 1H, 15N 
HSQC spectra were collected with the Bruker pulse program 
hsqcfpf3gpphwg [29]. Spectra were processed with Topspin 3.2 (Bruker, 
Billerica, MA), NMRPipe [30] and plotted using NMRglue [31]. For each 
titrant, 1–2 μL stock CaCl2 was added to a microcentrifuge test tube 
containing the NMR sample. The sample was then placed into a glass 
NMR tube, with care taken to avoid air bubbles. This was then placed in 
the NMR spectrometer and measurements taken. Chemical shift analysis 
was done using CcpNmr Analysis V3 [32,33]. Binding analysis was 
performed on the largest chemical shift perturbations (CSPs) using the 
combined chemical shift difference in both 15N and 1H [34]. CSPs were 
then plotted against the concentration of Ca2+ delivered and fit to a 
saturation binding model, given by: 
Δδ =
Kd + [L] + [P] −
̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅




where Δδ is the change in chemical shift upon addition of ligand, [P] is 
the concentration of fortilin, [L] is the concentration of ligand (or Ca2+), 
and Δδmax is the maximum chemical change upon saturation of fortilin 
with Ca2+. Curve fitting and error analysis was performed using 
Wolfram Mathematica. 
4.1.13. LC-MS based proteomics analysis 
Proteomic analysis was performed using a method established pre-
viously with modifications [35]. Excised gel pieces were de-stained in 
50 mM ammonium bicarbonate/50% acetonitrile, reduced in 10 mM 
DTT for 60 min at 56 ◦C, and alkylated in 55 mM iodoacetamide for 60 
min at room temperature in the dark. Gel pieces were then digested with 
proteomics grade trypsin (Thermo Fisher Scientific, Waltham, MA) 
overnight at 37 ◦C. Resulting peptide mixtures were chromatographi-
cally separated on a reverse-phase C18 column (10 cm × 75 μm, 3 μm, 
120 Å) and analyzed on a Velos Pro Dual-Pressure Linear Ion Trap mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA) as described 
previously [35]. 
Peptide spectral matching and protein identification were achieved 
by database search using Sequest HT algorithms in Proteome Discoverer 
2.2 (ThermoFisher Scientific, Waltham, MA). Raw spectral data were 
searched against a protein sequence database containing the anticipated 
sequences and UniProtKB/Swiss-Prot protein database for E. coli (ac-
quired from www.uniprot.org on November 3, 2020). Main search pa-
rameters included: trypsin, maximum missed cleavage site of two, 
precursor mass tolerance of 1.5 Da, fragment mass tolerance of 0.8 Da, 
fixed modification of cysteine carbamidomethylation (+57.021 Da), and 
variable modification of methionine oxidation (+15.995 Da). Decoy 
database search was performed to calculate false discovery rate (FDR). 
Proteins containing one or more peptides with FDR ≤0.01 were 
considered positively identified and reported. 
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